BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zemprocitinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zemprocitinib\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07237568-1413@assetmemo.bio
DTSTAMP:20261121T004443Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Zemprocitinib: Phase 3 readout est. (NCT07237568)
DESCRIPTION:Zemprocitinib\, phase 3.\nStudy: A Study to Evaluate Efficacy a
 nd Safety of LNK01001 in Adults With Ankylosing Spondylitis\nEstimated pri
 mary completion: November 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/zemprocitinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07237568
URL:https://assetmemo.bio/drug/zemprocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
